Table 2 Expression of markers in luminal neoplastic cells examined by immunohistochemistry

Normal yglands

8

24 ± 24.60 (5, 25-72)

38 ± 29 (6, 22-70)

100 ± 0 (8)

100 ± 0 (8) (ductal)

-

100 ± 0 (8) (terminal intralobular ducts)

Hyperpasia/ dysplasia

73

5.59 ± 17 (13, 2.10-87)

10.58 ± 25.54 (25, 1.30-100)

100 ± 0 (73)

100 ± 0 (72)^c (ductal)

-

100 ± 0 (29)^e (terminal intralobular ducts)

Benign tumors

6

15.55 ± 17.47 (3, 27-38)

26.97 ± 38.23 (4, 6-100)

100 ± 0 (6)

42.58 ± 36.62 (5, 7.5-100)

-

-

Malignant tumors

68

1.54 ± 9.18 (3, 4.80-70)

2.85 ± 13.86 (6, 2-87.3)

83.45 ± 30.22 (65, 2-100)

53.19 ± 34.73 (62, 0.5-100)

7.76 ± 17.83 (29, 0.5-100)

32.05 ± 32.96 (62, 0.5-100)

DC/IDPC

8

I

(1, 4.80%)^a

12.38 ± 25.42 (4, 2-73)

100 ± 0 (8)

27.31 ± 28.48 (5, 17.8-80)

-

(1, 34%)^f

Other subtypes

12

I

(1, 70%)^b

(1, 7%)^b

72.67 ± 32.35 (11, 33-100)

51.41 ± 37.74 (11, 1.2-100)

5.69 ± 16.83 (6, 5-56)

32.10 ± 36.62 (9, 0.5-100)

22

II

-

-

87.18 ± 25.39 (22, 5-100)

57.85 ± 32.88 (21, 7-98)

6.98 ± 10.06 (5, 0.5-28)

37.91 ± 29.96 (22, 0.5-100)

26

III

(1, 29.70%)^b

(1, 87.30%)^b

78.96 ± 35.79 (24, 2-100)

58.04 ± 34.80 (25, 3.3-100)

12.37 ± 25.39 (17, 0.5-100)

35.49 ± 33.84 (23, 0.5-100)

LN Metastases

9

-

-

81.33 ± 35.62 (9, 2-100)

50.83 ± 42.42 (9, 0.5-98)

5.33 ± 12.16 (3, 0.5-32.7)

28.47 ± 35.47 (9, 0.5-97)